
Immunomerevenue & market cap
Bothell, WashingtonFounded 2006
Public companyImmunome is a clinical-stage biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, focusing on improving outcomes for cancer patients.
Immunome revenue
Immunome's annual revenue was $6.9M in December 2025 (Stock Analysis). That is down 23% from $9M a year earlier.
$0
$2.5M
$5M
$7.5M
$0
–
$9M
$6.9M
20062007–2320242025
All 2 revenue readings, with sources
| As of | Revenue | Source |
|---|---|---|
| Dec 2024 | $9M | Stock Analysis |
| Dec 2025 | $6.9M | Stock Analysis |
Immunome market cap
Immunome is a public company. Its market capitalisation was $2.5B in September 2026.
Immunome FAQ
Categories
How this page is sourced
2 from public sources. Founder figures link to the second they were said; public figures name their source; estimates are marked EST and say whose they are. Not financial advice.
Updated Sep 29, 2026Data disclaimerReport a correctionClaim this profileRun Immunome? Join the podcast